About Anthology
Anthology is a company based in Cambridge (United States) founded in 2023 by Jing Zhang, Tzu-Chieh Tang, and Charles Jo. It operates as a Product-as-a-Service. Anthology offers products and services including Designer Genomes, Functional Proteins, and Engineered Microbes. Anthology operates in a competitive market with competitors including Tessera Therapeutics, Phase Genomics, Strateos, SeqOne and Hexagon Bio, among others.
- Headquarter Cambridge, United States
- Founders Jing Zhang, Tzu-Chieh Tang, Charles Jo
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Latest Funding Round
- Investors
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Anthology
Anthology offers a comprehensive portfolio of products and services, including Designer Genomes, Functional Proteins, and Engineered Microbes.
Designer genomes are created for diverse biomanufacturing applications.
Functional proteins are produced for healthy aging support.
Engineered microbes are used for carbon-neutral waste conversion.
People of Anthology
Unlock access to complete
Unlock access to complete
Funding Insights of Anthology
- Total Funding Total Funding
- Total Rounds 1
- Last Round Last Round
- First Round First Round
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2023 | Amount | Seed - Anthology | Valuation | Climate Capital |
|
Investors in Anthology
Anthology has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Climate Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital is invested in climate tech startups and entrepreneurs.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Anthology
Financial Statements - Anthology
Anthology Comparisons
Competitors of Anthology
Anthology operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Tessera Therapeutics, Phase Genomics, Strateos, SeqOne and Hexagon Bio, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
New genome engineering technology is provided for treating multiple diseases.
|
|
| domain | founded_year | HQ Location |
Laboratory and computational services for DNA proximity analysis are provided.
|
|
| domain | founded_year | HQ Location |
Provider of cloud based platform provides data driven information for biotech research
|
|
| domain | founded_year | HQ Location |
Bioinformatics tools for genome sequencing data analysis are provided.
|
|
| domain | founded_year | HQ Location |
Bioinformatics tools are provided for analyzing microbial genomic sequencing data.
|
|
| domain | founded_year | HQ Location |
Clinical gene sequencing services and duplication tests are provided.
|
Latest news on Anthology
Frequently Asked Questions about Anthology
Anthology was founded in 2023.
Anthology is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Jing Zhang is the current CEO of Anthology. They have also founded this company.
Anthology is focused on generating diverse designer genomes to address challenges in human, animal, and planetary health. Solutions are developed in the biotechnology sector, emphasizing synthetic biology and genomic engineering. Functional proteins are produced for healthy aging and animal welfare, while engineered microbes support carbon-neutral bioproduction by converting waste into valuable products. Scalable and efficient approaches are prioritized to promote a circular bioeconomy and reduce environmental impact.
Anthology's top competitors include Tessera Therapeutics, Phase Genomics and PreventionGenetics.
Anthology offers Designer Genomes, Functional Proteins, and Engineered Microbes.
Anthology has 1 investor. Key investors include Climate Capital.